SEC Tracker
Get the app

Lucid Diagnostics LUCD

Lucid Diagnostics FY 2022: revenue $377K, down 25%; diluted EPS −$1.55

Form
10-K
Filed
Period
Importance
Notable
Document
10-K
Exhibit 10.4
Material contract
Exhibit 10.5
Material contract
Exhibit 10.9
Material contract
Exhibit 10.16
Material contract
Exhibit 10.18
Material contract

Key figures from this report

These are the numbers Lucid Diagnostics reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$377K−25% from $500K in FY 202110-K income statement, on EDGAR
  2. Net income−$56.2MAgainst −$28.1M in FY 202110-K income statement, on EDGAR
  3. Diluted EPS−$1.55No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$22.5M−58% from $53.7M in FY 202110-K balance sheet, on EDGAR
  5. Cash from operations−$29.7MAgainst −$17.7M in FY 202110-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Lucid Diagnostics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Apyx Medical APYX public float $80M, Jun 30, 2025
  2. Encision ECIA
  3. Accuray ARAY public float $87M, Dec 31, 2025
  4. TELA Bio TELA public float $77M, Jun 30, 2025
  5. enVVeno Medical NVNO public float $76M, Jun 30, 2025